Vir Biotechnology, Inc. (VIR)
NASDAQ: VIR · Real-Time Price · USD
5.47
+0.02 (0.46%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Vir Biotechnology Revenue
In the year 2024, Vir Biotechnology had annual revenue of $74.21M, down -13.90%. Vir Biotechnology had revenue of $12.37M in the quarter ending December 31, 2024, a decrease of -26.29%.
Revenue (ttm)
$74.21M
Revenue Growth
-13.90%
P/S Ratio
10.10
Revenue / Employee
$181,875
Employees
408
Market Cap
754.29M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
VIR News
- 4 weeks ago - Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results - PRNewsWire
- 5 weeks ago - Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta - Business Wire
- 7 weeks ago - Vir Biotechnology, Inc. (VIR) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results - Business Wire
- 2 months ago - Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference - Business Wire
- 2 months ago - Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 - Business Wire
- 3 months ago - Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025 - Seeking Alpha
- 3 months ago - Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why - Benzinga